Related Experiment Video

Updated: Aug 5, 2026

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
07:38

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Published on: January 20, 2023

Evaluation of the effect of mavacamten on left ventricular function in obstructive hypertrophic cardiomyopathy using

Linlin Wan1,2,3, Xixi Chen1,2,3, Ziwei Huang1,2,3

  • 1Department of Echocardiography, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

Clinical Physiology and Functional Imaging
|July 27, 2026
PubMed

Insights

Mavacamten treatment for 12 weeks effectively reduced obstruction in obstructive hypertrophic cardiomyopathy (oHCM) patients. This therapy improved myocardial work efficiency and patient symptoms while preserving cardiac function.

Area of Science:

  • Cardiology
  • Cardiovascular Research
  • Pharmacology

Background:

  • Obstructive hypertrophic cardiomyopathy (oHCM) is a significant cause of heart disease.
  • Current treatments for oHCM have limitations.
  • Mavacamten is a novel therapeutic agent for oHCM.

Purpose of the Study:

  • To evaluate the effect of 12-week Mavacamten on left ventricular function in oHCM using myocardial work analysis.
  • To explore Mavacamten's role in myocardial energy metabolism.
  • To assess changes in hemodynamic and clinical parameters following Mavacamten treatment.

Main Methods:

  • A study involving 35 oHCM patients and 35 healthy controls.
  • Patients received 12-week Mavacamten treatment.
  • Measurements included LVOT gradient, LVEF, GLS, myocardial work parameters (GWI, GCW, GWW, GWE), mitral regurgitation, and SAM.

Main Results:

  • Mavacamten significantly reduced LVOT gradients, mitral regurgitation, and SAM.
  • Myocardial work showed decreased global work index (GWI), global constructive work (GCW), and global wasted work (GWW), with increased global wasted energy (GWE).
  • NT-proBNP levels decreased, and NYHA functional class improved, with no significant changes in LVEF or GLS.

Conclusions:

  • Mavacamten effectively reduces LVOT obstruction in oHCM patients.
  • The drug improves myocardial work efficiency and patient symptoms while preserving systolic function.
  • Myocardial work parameters show promise as non-invasive indicators for evaluating treatment efficacy in oHCM.
Abstract

Keywords:
left ventricular functionmavacamtenmyocardial workobstructive hypertrophic cardiomyopathy

More Related Videos

Assessment of Right Ventricular Structure and Function in Mouse Model of Pulmonary Artery Constriction by Transthoracic Echocardiography10:33

Assessment of Right Ventricular Structure and Function in Mouse Model of Pulmonary Artery Constriction by Transthoracic Echocardiography

Published on: February 3, 2014

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography08:13

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography

Published on: February 16, 2016

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.